PPT-Differences in the recommended initial therapy of COPD

according to GOLD 2006 and 2011 revisions Ivan Vyshnyvetskyy 1 Yuriy Mostov o y 2 Olexiy Onyshchenko 1 1 Department of Internal Medicine and General Practice Family Medicine Donetsk National Medical University Donetsk Ukraine. Kathleen McNamara, . PharmD. PGY1 Pharmacy Resident 2015-2016 NEIMEF & WHC. Therapy Goals & Assessment. Non-pharmacologic & Pharmacologic Therapy. Medications. Mechanism of Action. Adverse Effects. COPD is characterized by :. **Chronic airflow obstruction & accelerated . . loss of lung function which is progressive & . NOT. fully reversible.. ** COPD is preventable & treatable but . Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of . New Clinical Data?. Program Overview. Managing Stable COPD: Goals of Therapy. Updated GOLD Recommendations: . First-line Pharmacologic Therapy for Stable COPD. Dr Maxine Hardinge. Consultant Respiratory . Medicine . Oxford . University Hospitals NHS Foundation Trust. Aims of treatment – reducing risk and reducing symptoms. Inhaled therapy – . new Oxfordshire . Julia Rogers, MSN, RN, CNS, FNP-BC. Diagnosis and Overview. Therapeutic . Options. Manage Stable COPD. Manage . Exacerbations. . Airway and systemic inflammation. Under-recognized / under-diagnosed. Dietetic Intern. Andrews University. Introduction. Patient’s Initials: NM. Primary . Problem . & other . medical conditions: . COPD. , DM, IBS, Pneumonia, IgA . deficiency. Height: 160.02. Weight: 107.2. Patient Background. Daishi . Hayato. Age 65. Male. Asian American. Retired. Wife and 4 adult children. Father had lung cancer . Primary Diagnosis: . Acute respiratory distress, COPD, peripheral vascular disease with intermittent . Objectives of Treatment. GOLD 2018: Pharmacologic Treatment Recommendations. GOLD 2018: Pharmacologic Treatment Recommendations (. c. ont). GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D. Clinical Trial Evidence. Introduction . Therapeutic Recommendations . Therapeutic Recommendations in Groups B and D . Bronchodilators in Stable COPD. ICS in Stable COPD. COPD . Potential AEs of ICS Treatment. in the Treatment of . Asthma and COPD. Margaret Miklich, . PharmD. , BCACP. Clinical Assistant Professor. 1. m. argaret.miklich@temple.edu. I have no conflicts of interest to disclose.. 2. Pharmacist Objectives. in the Treatment of . Asthma and COPD. Margaret Miklich, . PharmD. , BCACP. Clinical Assistant Professor. 1. m. argaret.miklich@temple.edu. I have no conflicts of interest to disclose.. 2. Pharmacist Objectives. MA-PF-AI-SG-0006-1. Date of preparation, March 2021. . This is a case study of an actual patient, who . provided verbal informed consent. Case description. Name: HVT. Age: 65 years . Gender: male. History and comorbidities: . disease . is characterized by . . airflow limitation that is not fully . reversible.. The . airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. . An ASTRO Clinical Practice Guideline . Developed in collaboration with the American Academy of Otolaryngology-Head and Neck Surgery, American Society of Clinical Oncology, and Society of Surgical Oncology.